SEATTLE, July 24, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today
announced the appointment of Guy F. Cipriani as Vice President,
Business Development, effective July 23, 2012. Mr. Cipriani's will
lead Oncothyreon's business development activities for its pipeline of
small molecule and immunotherapy product candidates.
"Mr. Cipriani is a seasoned executive with more than 12 years of
business development experience in the biotechnology and pharmaceutical
sectors, and we are pleased to have him join the Oncothyreon team,"
said Robert L. Kirkman, M.D., President and Chief Executive Officer of
Oncothyreon. "He will be an integral part of our efforts to maximize
the opportunities for our wholly owned product candidates as well as
the building of our product development pipeline."
Mr. Cipriani most recently served as Chief Business Officer for Immune
Design Corp, a privately held biotechnology company developing
therapeutic vaccines and immunotherapies for infectious diseases,
cancer and allergy. Prior to joining Immune Design in November of
2011, he served as Vice President, Business Development for Cardiome
Pharmaceuticals, a publicly traded biotechnology company, from 2005 to
November 2011. At Cardiome, Mr. Capriani directed the out-licensing of
Cardiome's Phase 3 product candidate to Merck & Company and in-licensed
multiple product candidates. Prior to Cardiome, Mr. Capriani worked as
Senior Director, Business Development for Transform Pharmaceutical,
Inc., a biotechnology company acquired by Johnson & Johnson in April
2005. He also worked in corporate business development for five years
at Eli Lilly and Company and as a management consultant with Accenture.
Mr. Capriani received an M.B.A. from the Kellogg School of Management
at Northwestern University and a B.S. in electrical engineering from
Rochester Institute of Technology.
Oncothyreon is a biotechnology company specializing in the development
of innovative therapeutic products for the treatment of cancer.
Oncothyreon's goal is to develop and commercialize novel synthetic
vaccines and targeted small molecules that have the potential to
improve the lives and outcomes of cancer patients. For more
information, visit www.oncothyreon.com.
SOURCE Oncothyreon Inc.